statistiche ricercatore

NAPOLITANO, FABIANA

Distribuzione geografica

Continente	#
AS - Asia	1.294
NA - Nord America	1.262
EU - Europa	1.061
SA - Sud America	141
Continente sconosciuto - Info sul continente non disponibili	66
AF - Africa	31
OC - Oceania	2
Totale	3.857

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1.188
SG - Singapore	487
RU - Federazione Russa	398
IT - Italia	396
CN - Cina	267
VN - Vietnam	252
BR - Brasile	109
DE - Germania	93
HK - Hong Kong	89
IN - India	48
BD - Bangladesh	47
CA - Canada	41
FR - Francia	41
NL - Olanda	32
FI - Finlandia	27
JP - Giappone	26
GB - Regno Unito	23
KR - Corea	21
CI - Costa d'Avorio	14
MX - Messico	14
AR - Argentina	13
PK - Pakistan	13
EC - Ecuador	8
UA - Ucraina	8
ZA - Sudafrica	8
IQ - Iraq	7
PL - Polonia	7
BE - Belgio	6
MY - Malesia	6
SE - Svezia	6
CR - Costa Rica	5
ES - Italia	5
TH - Thailandia	5
UZ - Uzbekistan	5
VE - Venezuela	5
ID - Indonesia	4
TR - Turchia	4
HN - Honduras	3
IL - Israele	3
JM - Giamaica	3
LT - Lituania	3
AT - Austria	2
AU - Australia	2
CL - Cile	2
CO - Colombia	2
CZ - Repubblica Ceca	2
EE - Estonia	2
EG - Egitto	2
PH - Filippine	2
PT - Portogallo	2
PY - Paraguay	2
RO - Romania	2
SV - El Salvador	2
TN - Tunisia	2
AE - Emirati Arabi Uniti	1
AM - Armenia	1
AZ - Azerbaigian	1
BF - Burkina Faso	1
BG - Bulgaria	1
CG - Congo	1
CH - Svizzera	1
CY - Cipro	1
DZ - Algeria	1
GR - Grecia	1
GT - Guatemala	1
JO - Giordania	1
KE - Kenya	1
KN - Saint Kitts e Nevis	1
MD - Moldavia	1
NI - Nicaragua	1
OM - Oman	1
PA - Panama	1
PR - Porto Rico	1
RS - Serbia	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
TT - Trinidad e Tobago	1
TW - Taiwan	1
ZM - Zambia	1
Totale	3.791

Salva come PNG Salva come JPEG

Città	#
Singapore	261
San Jose	205
Ashburn	162
Naples	159
Hefei	100
Ho Chi Minh City	87
Hong Kong	85
Moscow	84
Council Bluffs	79
Beijing	67
Santa Clara	59
Dallas	52
Hanoi	43
Munich	43
Chandler	39
Los Angeles	35
Lauterbourg	24
Kochi	23
Amsterdam	22
New York	22
Tokyo	21
The Dalles	20
Rome	18
Seoul	17
São Paulo	17
Da Nang	16
Milan	16
Turku	16
Napoli	15
Toronto	13
Buffalo	12
Frankfurt am Main	12
Chicago	11
Falkenstein	11
Haiphong	10
Millbury	10
Montreal	10
Redondo Beach	10
Boston	9
Helsinki	9
Lawrence	9
Pune	9
Brooklyn	8
Seattle	8
Turin	8
Atlanta	7
Mexico City	7
Ninh Bình	7
Warsaw	7
Casoria	6
Des Moines	6
Guayaquil	6
Houston	6
Nuremberg	6
Orem	6
Phoenix	6
Denver	5
Johannesburg	5
London	5
San Francisco	5
Stockholm	5
Tashkent	5
Baghdad	4
Bologna	4
Brussels	4
Charlotte	4
Düsseldorf	4
Formia	4
Fucecchio	4
Kuala Lumpur	4
Lahore	4
Long Xuyen	4
Poplar	4
Quảng Ngãi	4
Salerno	4
Shanghai	4
Belo Horizonte	3
Bengaluru	3
Can Tho	3
Casagiove	3
Chengdu	3
Chennai	3
Fort Worth	3
Hải Dương	3
Islamabad	3
Leicester	3
Ottawa	3
Philadelphia	3
Piscataway	3
Pomigliano d'Arco	3
Pozzuoli	3
Quận Ba	3
Redwood City	3
San José	3
Acalanes Ridge	2
Afragola	2
Alexandria	2
Ankara	2
Athens	2
Aurora	2
Totale	2.188

Salva come PNG Salva come JPEG

Nome	#
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists	203
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity	197
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors	179
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	178
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.	173
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations	171
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study	170
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities	169
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules	166
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma	159
Mechanisms of resistance to mTOR inhibitors	155
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer	151
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges	150
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review	148
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	145
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer	143
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer	140
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis	138
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study	135
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	132
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC	131
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors	111
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes	110
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer	100
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer	30
Mapping cellular interactions from spatially resolved transcriptomics data	29
Censoring in trials testing immunotherapy in advanced cancers: a systematic review and a meta-research study	25
Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals	24
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study	18
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer	17
Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation	16
Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer	12
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis	11
CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer	11
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations	10
Totale	3.857

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	12.487
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	12.487

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	71	0	0	0	7	1	3	3	4	4	7	20	22
2022/2023	180	15	10	5	3	19	16	12	20	30	25	14	11
2023/2024	190	4	18	43	16	7	32	3	22	6	6	16	17
2024/2025	948	28	21	5	17	26	75	90	82	49	138	336	81
2025/2026	1.945	192	148	251	160	290	82	201	93	228	109	68	123
2026/2027	416	61	72	102	181	0	0	0	0	0	0	0	0
Totale													3.857